What is the 13F Pro Quality Score for BIO?

13F Pro ranks BIO-RAD LABORATORIES, INC. (BIO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BIO's current score at https://13fpro.ai/research/BIO (free sign-up required for the full ranking).

Where does 13F Pro source BIO data?

All BIO-RAD LABORATORIES, INC. fundamentals and ownership data come directly from SEC EDGAR. BIO-RAD LABORATORIES, INC. files with the SEC under CIK 12208. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BIO in?

BIO-RAD LABORATORIES, INC. (BIO) is classified in the Technology sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/technology.

How often is BIO research updated on 13F Pro?

BIO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BIO-RAD LABORATORIES, INC.(BIO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Technology →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 12208 BIO stock profile & AI dashboard →

13F Pro Quality Score

40.3/100

Rank #1,940 of 2,879 stocks

View Technology peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

25.1/100

Profitability

19.2/100

Balance Sheet

24.5/100

Earnings Quality

30.0/100

Free Cash Flow

70.3/100

Institutional Flow

76.3/100

Revenue Scale

66.1/100

Dilution Risk

39.3/100

BIO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BIO-RAD LABORATORIES, INC. (BIO), a Technology sector company. 13F Pro's AI-powered ranking engine scores BIO at 40.3/100 on a 32-signal composite quality model, placing it at rank #1,940 of 2,879 stocks — the bottom half of the AI-ranked universe. BIO scores in the top quartile across institutional flow (76.3). Areas of concern include profitability (19.2) and balance sheet strength (24.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 39.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), BIO-RAD LABORATORIES, INC. reports quarterly revenue of $592.1M, net income of $-527.1M, an operating margin of 5.8%. Top institutional holders of BIO by reported 13-F value include First Eagle Investment Management,, BlackRock,, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. BIO trades on the NYSE exchange and files with the SEC under CIK 12208. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIO-RAD LABORATORIES, INC. directly from SEC EDGAR. BIO-RAD LABORATORIES, INC.'s 13F Pro composite quality score has ranged between 33 and 80 since 2021, currently 40.3 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.

Revenue

Q1 2026

$592.1M

Net Income

Q1 2026

$-527.1M

Free Cash Flow

Q1 2026

$78.1M

Operating Margin

Q1 2026

5.8%

ROIC

Q1 2026

0.4%

D/E Ratio

Q1 2026

0.18

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+0.7% YoY

$2.58BFY 2025

FY21 $2.92BFY22 $2.80BFY24 $2.57BFY25 $2.58B

Net Income

+141.2% YoY

$759.9MFY 2025

FY21 $4.25BFY22 $-3.63BFY24 $-1.84BFY25 $759.9M

Operating Income

-82.5% YoY

$47.2MFY 2025

FY21 $500.3MFY22 $482.6MFY24 $269.0MFY25 $47.2M

EPS (Diluted)

+142.6% YoY

$27.85FY 2025

FY21 $140.83FY22 $-121.79FY24 $-65.36FY25 $27.85

Total Assets

+12.9% YoY

$10.58BFY 2025

FY21 $17.78BFY22 $13.50BFY24 $9.36BFY25 $10.58B

Total Debt

+0.8% YoY

$1.21BFY 2025

FY21 $10.5MFY22 $1.20BFY24 $1.20BFY25 $1.21B

Op. Cash Flow

+16.9% YoY

$532.2MFY 2025

FY21 $669.5MFY22 $194.4MFY24 $455.2MFY25 $532.2M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$2.58B +0.7%	$2.57B -8.4%	$2.80B -4.1%	$2.92B +14.8%	$2.55B +10.1%	$2.31B
Net Income	$759.9M +141.2%	$-1.84B +49.2%	$-3.63B -185.3%	$4.25B +11.5%	$3.81B +116.9%	$1.76B
Operating Income	$47.2M -82.5%	$269.0M -44.3%	$482.6M -3.5%	$500.3M +18.8%	$421.3M +83.5%	$229.7M
EPS (Diluted)	$27.85 +142.6%	$-65.36 +46.3%	$-121.79 -186.5%	$140.83 +11.4%	$126.47 +117.0%	$58.27
Total Assets	$10.58B +12.9%	$9.36B -30.6%	$13.50B -24.0%	$17.78B +37.0%	$12.97B +62.0%	$8.01B
Total Debt	$1.21B +0.8%	$1.20B +0.2%	$1.20B +11291.6%	$10.5M -14.2%	$12.3M -9.7%	$13.6M
Operating Cash Flow	$532.2M +16.9%	$455.2M +134.2%	$194.4M -71.0%	$669.5M +14.4%	$585.0M +27.8%	$457.9M

AI Insight: BIO Financial Trends

Bio-Rad shows volatile profitability with net income swinging from $720M in Q4 2025 to -$527M in Q1 2026, while revenue remains range-bound.

• Revenue fluctuated between $585M-$693M across eight quarters with no clear growth trajectory, ending at $592M in Q1 2026.

• Net income exhibited extreme volatility, ranging from -$2,166M to $720M, with five out of eight quarters showing losses.

• Operating cash flow remained relatively stable between $98M-$165M despite earnings volatility, averaging $128M per quarter.

⚠ Operating income turned negative to -$119M in Q4 2025, the only negative quarter in the period.

⚠ Total debt remained flat around $1,200M while equity swings of $700M+ suggest significant non-cash charges affecting book value.

AI Insight: BIO Ratio Trends

BIO-RAD exhibits extreme quarterly volatility with operating margins swinging from -17.2% to 15.9% across recent periods.

• Operating margin deteriorated from 15.9% in Q2 2024 to 2.2% TTM, reflecting significant operational challenges.

• Net profit margins oscillated wildly between 103.9% and -107.2% across quarters, indicating substantial non-operating impacts.

• ROIC declined from 5.1% in Q2 2024 to 0.7% TTM, showing reduced capital efficiency.

• Debt-to-equity ratio remained stable around 0.16-0.18 throughout the period, indicating consistent leverage.

⚠ Operating margin turned deeply negative at -17.2% in Q4 2025, the worst quarterly performance in the dataset.

⚠ ROIC turned negative at -5.5% in Q4 2025, indicating capital destruction in that quarter.

⚠ Extreme quarterly earnings volatility suggests significant one-time items or operational instability requiring monitoring.

Get alerted when BIO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BIO-RAD LABORATORIES, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BIO

First Eagle Investment Management, LLC
$725.5M2,602,772 sh
BlackRock, Inc.
$468.3M1,680,060 sh
DIMENSIONAL FUND ADVISORS LP
$303.6M1,089,323 sh
VANGUARD CAPITAL MANAGEMENT LLC
$231.7M831,165 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$231.1M829,186 sh
ARIEL INVESTMENTS, LLC
$219.1M785,961 sh
EARNEST PARTNERS LLC
$164.1M588,731 sh
STATE STREET CORP
$156.0M559,570 sh
Capital World Investors
$125.4M450,000 sh
BANK OF AMERICA CORP /DE/
$124.0M444,957 sh

Fund	Value	Shares
First Eagle Investment Management, LLC	$725.5M	2,602,772
BlackRock, Inc.	$468.3M	1,680,060
DIMENSIONAL FUND ADVISORS LP	$303.6M	1,089,323
VANGUARD CAPITAL MANAGEMENT LLC	$231.7M	831,165
VANGUARD PORTFOLIO MANAGEMENT LLC	$231.1M	829,186
ARIEL INVESTMENTS, LLC	$219.1M	785,961
EARNEST PARTNERS LLC	$164.1M	588,731
STATE STREET CORP	$156.0M	559,570
Capital World Investors	$125.4M	450,000
BANK OF AMERICA CORP /DE/	$124.0M	444,957

More Technology Companies

View all Technology →

AGILENT TECHNOLOGIES, INC.

AAOI

APPLIED OPTOELECTRONICS, INC.

AAPL

Apple Inc.

ABNB

Airbnb, Inc.

ACCL

Acco Group Holdings Ltd

ACCS

ACCESS Newswire Inc.

ACFN

ACORN ENERGY, INC.

ACIW

ACI WORLDWIDE, INC.

Put BIO on your watchlist

Track score changes the day BIO-RAD LABORATORIES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BIO a good stock to buy?

13F Pro's AI-powered analysis of BIO-RAD LABORATORIES, INC. (BIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BIO are available on the BIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BIO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIO-RAD LABORATORIES, INC.'s investment landscape.